Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
12,352.35-3.15
Stock Analysis, IPO, Mutual Funds, Bonds & More
GST profiteering: Rs 230-crore penalty on Johnson & Johnson

The authority said it found it ‘surprising’ that the FMCG major had not added the tax cost and losses to prices of products between July 1 and November 14, 2017, but had chosen to do so from November 15, when it was supposed to have reduced prices due to the rate reduction to 18% from 28%.

Biocon extends licensing pact with Equillium for itolizumab

Itolizumab, a first-in-class humanized anti-CD6 monoclonal antibody, is developed by Biocon and launched in 2013 in India under the brand name ALZUMAb to treat moderate to severe plaque psoriasis, a skin disease.

SPV Foundation posts Rs 3 cr grant for bioscience research; TIFR scientist Vidita Vaidya bags research grant

Vidita’s Neurobiology lab at TIFR currently studies the molecular, epigenetic and cellular changes that contribute to persistent alterations in human behaviour. It also focusses on molecular and cellular adaptations that arise from sustained antidepressant treatment.

Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licence

This additional approval of its new manufacturing facility for pegfilgrastim in Bengaluru will enable the biotechnology major to enable its arm Biocon Biologics and Mylan to scale up capacity multi-fold and address the growing market opportunities in US and other global markets.

NCLAT gives 30 days more to Sterling Biotech promoters to settle dues

A three-member bench headed by Chairperson Justice S J Mukhopadhaya also said the Enforcement Directorate will probe and ascertain whether the money paid by the promoters is not from proceeds of crime. The promoters of the company include absconding Nitin Jayantilal Sandesara and Chetankumar Jayantilal Sandesara.

Advent set to buy controlling stake in Bharat Serum

Kotak PE and OrbiMed together that hold 23% stake in Mumbai-based biopharma company Bharat Serums and Vaccines (BSV) are exiting through this sale. The rest of the stake is with the Daftary family who are relinquishing control but will stay on as a minority partner, said people in the know. Advent will become the largest shareholder in the company.

Processes must be robust; merely being better no longer an option: Siddharth Mittal, Managing Director, Biocon

We have a very good track record on GMP compliance. We are taking a digital journey in strengthening our quality system, which will help us be dependent on systems and processes and less on people, says Siddharth Mittal, MD, Biocon.

Biocon number six in top 10 Global Biotech Employers ranking for 2019

Biocon continues to be the only company from Asia to feature on the prestigious US-based 'Science' magazine's annual 'Science Careers Top 20 Employers' list, since its debut in 2012.

Biocon, Mylan launch insulin biosimilar in Australia

The biotechnology major and pharmaceutical company Mylan N V announced the launch of their insulin biosimilar Semglee.

Need ED's satisfaction over dues payments made by Sterling promoters: NCLAT

The tribunal also said the promoters will have to settle their case with the creditors within a specified period.

USFDA issues response letter for new drug application for insulin glargine: Biocon

USFDA issues response letter for new drug application for insulin glargine: Biocon

Biocon is confident of addressing these observations through a corrective and preventive action plan in a timely manner, it added.

Biocon's Malaysian arm gets EU GMP certification for insulin manufacturing facility

Biocon's Malaysian arm gets EU GMP certification for insulin manufacturing facility

The integrated insulins facility in Malaysia manufactures drug substance and drug products in vials, cartridges, and insulin delivery devices was inspected in May 2019.

USFDA issues 12 observations for 3 Biocon units in Malaysia

USFDA issues 12 observations for 3 Biocon units in Malaysia

US health regulator has issued 12 observations after the inspection of three of Biocon's units in Malaysia.

Biocon board approves sale of branded formulations business to subsidiary

Biocon board approves sale of branded formulations business to subsidiary

The Board of Directors in its meeting approved the sale of Branded Formulations India (BFI) business to Biocon Biologics India (BBIL).

NCLT refers Sterling Biotech for liquidation

NCLT refers Sterling Biotech for liquidation

“The tribunal has decided to refer the company for insolvency in a verbal order,” said one of the people.

CCI to hold off Monsanto probe for now

CCI to hold off Monsanto probe for now

The CCI had initiated a probe against the company and the role of its officials and directors following a complaint by several local seed companies led by Nuziveedu Seeds.

Load More...
1

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service

BACK TO TOP